Showing results (11-20 of 50) with videos related to

Sort By:
Pageof 5
Oncology (Williston Park, N.Y.)|February 17, 2017
Novel and Expanded Oncology Drug Approvals of 2016-PART 2: New Options in the Management of Hematologic MalignanciesTodd C Knepper, James Saller, Christine M Walko
Anti-Cancer Drugs|March 2, 2011
Response to degarelix after resistance to luteinizing hormone-releasing hormone agonist therapy for metastatic prostate cancerRyan S Raddin, Christine M Walko, Young E Whang
Pharmacogenomics and Personalized Medicine|January 31, 2019
Precision medicine approaches for the management of Ewing sarcoma: current perspectivesVictoria T Rizk, Christine M Walko, Andrew S Brohl
The Annals of Pharmacotherapy|April 22, 2004
Treatment of vancomycin-resistant enterococcus with quinupristin/dalfopristin and high-dose ampicillinJ Audis Bethea, Christine M Walko, Patricia A Targos
The Annals of Pharmacotherapy|November 22, 2013
Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumorsDaniel J Crona, Meredith D Keisler, Christine M Walko
Clinical Pharmacology and Therapeutics|June 15, 2020
Developing Drugs for Tissue-Agnostic Indications: A Paradigm Shift in Leveraging Cancer Biology for Precision MedicineNathan D Seligson, Todd C Knepper, Susanne Ragg, et al.
Journal of Pharmaceutical and Biomedical Analysis|September 15, 2007
Enantioselective liquid chromatography-mass spectrometry assay for the determination of ifosfamide and identification of the N-dechloroethylated metabolites of ifosfamide in human plasmaRegina V Oliveira, Joelle M Onorato, Danuta Siluk, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 15, 2018
Response to Checkpoint Inhibitor Therapy in Advanced Classic Kaposi Sarcoma: A Case Report and Immunogenomic StudyJames Saller, Christine M Walko, Sherri Z Millis, et al.
Cancer Control : Journal of the Moffitt Cancer Center|October 8, 2021
Durable Progression-Free Survival With the Use of BRAF and MEK Inhibitors in Four Cases With BRAF V600E-Mutated GliomasMichael J Fusco, Yolanda Piña, Robert J Macaulay, et al.
Pharmacotherapy|February 25, 2017
Quantitation of Targetable Somatic Mutations Among Patients Evaluated by a Personalized Medicine Clinical Service: Considerations for Off-Label Drug UseCory M Vela, Todd C Knepper, Nancy K Gillis, et al.
Pageof 5